-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Can Selectin and Invariant Natural Killer T-Cell Therapies Meet the Needs of People with Sickle Cell Disease?

Program: Education Program
Session: Optimizing Therapy in Sickle Cell Disease
Saturday, December 5, 2015, 9:30 AM-11:00 AM
Chapin Theater (W320), Level 3 (Orange County Convention Center)
Sunday, December 6, 2015, 9:30 AM-11:00 AM
Hall E1, Level 2 (Orange County Convention Center)

Joshua Field, MD, MS

BloodCenter of Wisconsin, Milwaukee, WI

Disclosures: Field: NKT Therapeutics: Consultancy , Research Funding ; Astellas: Research Funding . Off Label Use: Regadenoson is FDA-approved for use during myocardial imaging. I will discuss the investigational use of regadenoson for the treatment of pain episodes in sickle cell disease. .

See more of: Optimizing Therapy in Sickle Cell Disease
See more of: Education Program
<< Previous Presentation | Next Presentation